Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: A multi-institutional study.
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inadequate antimicrobial treatment is an independent determinant of hospital mortality, and fungal bloodstream infections are among the types of infection with the highest rates of inappropriate initial treatment. Because of significant potential for reducing high mortality rates, we sought to assess the impact of delayed treatment across multiple study sites. The goals our analyses were to establish the frequency and duration of delayed antifungal treatment and to evaluate the relationship between treatment delay and mortality. METHODS: We conducted a retrospective cohort study of patients with candidemia from 4 medical centers who were prescribed fluconazole. Time to initiation of fluconazole therapy was calculated by subtracting the date on which fluconazole therapy was initiated from the culture date of the first blood sample positive for yeast. RESULTS: A total of 230 patients (51% male; mean age +/- standard deviation, 56 +/- 17 years) were identified; 192 of these had not been given prior treatment with fluconazole. Patients most commonly had nonsurgical hospital admission (162 patients [70%]) with a central line catheter (193 [84%]), diabetes (68 [30%]), or cancer (54 [24%]). Candida species causing infection included Candida albicans (129 patients [56%]), Candida glabrata (38 [16%]), Candida parapsilosis (25 [11%]), or Candida tropicalis (15 [7%]). The number of days to the initiation of antifungal treatment was 0 (92 patients [40%]), 1 (38 [17%]), 2 (33 [14%]) or > or = 3 (29 [12%]). Mortality rates were lowest for patients who began therapy on day 0 (14 patients [15%]) followed by patients who began on day 1 (9 [24%]), day 2 (12 [37%]), or day > or = 3 (12 [41%]) (P = .0009 for trend). Multivariate logistic regression was used to calculate independent predictors of mortality, which include increased time until fluconazole initiation (odds ratio, 1.42; P < .05) and Acute Physiology and Chronic Health Evaluation II score (1-point increments; odds ratio, 1.13; P < .05). CONCLUSION: A delay in the initiation of fluconazole therapy in hospitalized patients with candidemia significantly impacted mortality. New methods to avoid delays in appropriate antifungal therapy, such as rapid diagnostic tests or identification of unique risk factors, are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mortality reduction associated with early antimicrobials appears strongest in patients with septic shock, where studies have reported a strong association between time to antibiotics and death in patients with septic shock but weaker associations in patients without septic shock (98,109,110).”
From Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. (2021) · cites this paper as [109]
In the citing paper
“Blood cultures take an average of 2–3 days to grow Candida, or longer depending on the species.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Attributable mortality from IC remains high and increases with delays in treatment.”
From Epidemiology of Invasive Candidiasis (2024) · cites this paper as [135]
In the citing paper
“Some observational studies suggested that prompt initiation of appropriate empiric antifungal therapy may be associated with a reduction in mortality, however these studies do not prove a causal relationship between antifungal therapy and outcome, nor do they clarify the role of timing of treatment, and some other studies have failed to show this association [167, 171–173].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [171]
In the citing paper
“Multivariate analysis in this study also provided a strong association between delay in therapy and mortality.”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [46]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P., & Edmond, M. B. (2004) · Clinical Infectious Diseases · doi:10.1086/421946 · Cited by 4,496 · cited 11×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 2×
“of inappropriate initial treatment [6].”
BackgroundMorrell, M., Fraser, V. J., & Kollef, M. H. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3640-3645.2005 · Cited by 1,286 · cited 5×
“Delaying antifungal therapy appears to be a common practice, and the impact on mortality may be significant [8, 10].”
BackgroundResultInfluentialAttributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140 · cited 2×
“Attributable mortality rates of 49% were also shown among patients with candidemia, compared with uninfected control subjects matched for age, sex, date of hospital admission, underlying diseases, length of time at risk, and type of surgical procedure [5].”
BackgroundPfaller, M. A., Diekema, D. J., Jones, R. N., Sader, H. S., Fluit, A. C., Hollis, R. J., Messer, S. A., & The SENTRY Participant Group (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.9.3254-3259.2001 · Cited by 521 · cited 1×
“[1].”
Morgan, J., Meltzer, M. I., Plikaytis, B. D., Sofair, A. N., Huie-White, S., Wilcox, S., Harrison, L. H., Seaberg, E. C., Hajjeh, R. A., & Teutsch, S. M. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502581 · Cited by 437 · cited 2×
“attributable mortality remains 19%–49% [2, 5].”
Pfaller, M. A., Jones, R. N., Messer, S. A., Edmond, M. B., & Wenzel, R. P. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(97)00240-x · Cited by 331 · cited 10×
“By contrast, gram-positive bacteria, such as coagulase-negative staphylococci, S. aureus, and Enterococcus species, account for 60% of all BSIs [16].”
BackgroundInfluentialThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310 · cited 1×
“of 8 cases per 100,000 population [2–4].”
Leinberger, D. M., Schumacher, U., Autenrieth, I. B., & Bachmann, T. T. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.4943-4953.2005 · Cited by 155 · cited 1×
“Development of nonculture methods for the rapid diagnosis of candidemia in patients with BSI may also significantly improve the ability to quickly prescribe appropriate antifungal therapy [19, 20].”
Epidemiology and Prognostic Determinants of Bloodstream Infections in Surgical Intensive Care
Harbarth, S. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.12.1353 · Cited by 135
Cited by
Items 601–700 of 1,000
Liu, J., Huang, H., Li, Y., Liu, L., Li, J., Liu, Z., Lu, J., Ouyang, J., Song, Y., Zhou, D., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4441-8 · Cited by 16
Candidemia in Siriraj Hospital: epidemiology and factors associated with mortality.
Boonyasiri, A., Jearanaisilavong, J., & Assanasen, S. (2013) · PubMed · Cited by 18
Arias, S. G., Denis, O., Montesinos, I., Cherifi, S., Deyi, V. Y. M., & Zech, F. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2825-3 · Cited by 16
Baronia, A. K., Sharma, P., Yadav, R., Marak, R. S. K., & Singh, R. K. (2017) · Indian Journal of Critical Care Medicine · doi:10.4103/ijccm.ijccm_33_17 · Cited by 16
“[2,3] Delay in the initiation of appropriate antifungal therapy is associated with increased mortality and morbidity.[4,5] Early identification of invasive candidiasis is essential for appropriate management and includes identification of high‐risk groups.”
BackgroundThe Black Yeasts: an Update on Species Identification and Diagnosis
Cañete-Gibas, C. F., & Wiederhold, N. P. (2018) · Current Fungal Infection Reports · doi:10.1007/s12281-018-0314-0 · Cited by 16
Bal, A. M., & McGill, M. (2018) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2018.203 · Cited by 17
Bloos, F., Held, J., Schlattmann, P., Brillinger, N., Kurzai, O., Cornely, O. A., & Thomas-Rüddel, D. O. (2018) · Trials · doi:10.1186/s13063-018-2868-0 · Cited by 17
Opportunistic and Systemic Fungi
Kosmidis, C., & Denning, D. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-7020-6285-8.00189-1 · Cited by 19
Defining standards of CARE for invasive fungal diseases in the ICU
Cuenca‐Estrella, M., Kett, D. H., & Wauters, J. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz038 · Cited by 18
Antifungal Resistance Testing and Implications for Management
Badali, H., & Wiederhold, N. P. (2019) · Current Fungal Infection Reports · doi:10.1007/s12281-019-00354-6 · Cited by 17
Candidemia Incidence in Recipients of Parenteral Nutrition
Stratman, R. C., Martin, C. A., Rapp, R. P., Berger, R., & Magnuson, B. L. (2010) · Nutrition in Clinical Practice · doi:10.1177/0884533610368704 · Cited by 21
Hope, W. W. (2009) · Medical Mycology · doi:10.1080/13693780802510232 · Cited by 18
Adıgüzel, N., Karakurt, Z., Güngör, G., Moçin, Ö. Y., Acartürk, E., Soğukpınar, Ö., & Baran, R. (2010) · PubMed · Cited by 19
Sensitive and rapid RT-qPCR quantification of pathogenic Candida species in human blood
Ogata, K., Matsuda, K., Tsuji, H., & Nomoto, K. (2015) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2015.07.021 · Cited by 19
Changing trends in the epidemiology of Candida blood stream infections: A matter for concern?*
Sobel, J. D. (2010) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181d16866 · Cited by 16
Candidemias y candidiasis invasivas nosocomiales
Quindós, G. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.09.021 · Cited by 16
Treatment Principles for Candida and Cryptococcus
Whitney, L., & Bicanic, T. A. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024158 · Cited by 17
“2005), and mortality is directly correlated with delays in initiation of adequate antifungal therapy (Morrell et al. 2005; Garey et al. 2006).”
BackgroundAndes, D. R., & Lepak, A. J. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis446 · Cited by 17
Huston, J. M., Kreiner, L. A., Ho, V. P., Sanders, J. M., & Duane, T. M. (2019) · Surgical Infections · doi:10.1089/sur.2019.062 · Cited by 15
Oral mycobiome identification in atopic dermatitis, leukemia, and HIV patients – a systematic review
Sodré, C. S., Rodrigues, P. M. G., Vieira, M. S., da Silva, A. M. P., Gonçalves, L. S., Ribeiro, M. G., & Ferreira, D. D. C. (2020) · Journal of Oral Microbiology · doi:10.1080/20002297.2020.1807179 · Cited by 16
“To investigate mycobiota the internal transcribed spacer (ITS) between 18S and 28 S rRna genes is the most used locus [83].”
d’Enfert, C., & Bougnoux, M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.00139-2 · Cited by 16
Clinical and Microbiological Characteristics of Candidemia Cases in Saudi Arabia
Alkhalifa, W., Alhawaj, H., Alamri, A. M., Alturki, F., Alshahrani, M. S. S., & Alnimr, A. M. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s411865 · Cited by 15
Giacobbe, D. R., Marelli, C., Mora, S., Guastavino, S., Russo, C., Brucci, G., Limongelli, A., Vena, A., Mikulska, M., Tayefi, M., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2285454 · Cited by 15
“…patients who truly have candidemia (or mixed candidemia and bacteremia), given the reported increase in mortality associated with delays in therapy [8, 9]; and (ii) avoid as much as possible useless antifungal treatment in patients with bacteremia only, in line with antifungal stewardship…”
BackgroundPosteraro, B., Sanguinetti, M., Boccia, S., Feo, E. D., Sorda, M. L., Tana, M., Tirone, C., Aurilia, C., Vendettuoli, V., Fadda, G., et al. (2010) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e3181da866d · Cited by 15
“In general, difficulties exist in establishing an early diagnosis of Candida infection, and the consequent delay to appropriate therapy leads to increased morbidity and mortality.(30,31) As recently reviewed by Méan et al,(6) antigen-based tests have been shown to perform well in clinical studies including 5% to 30% o…”
Recomendaciones para el manejo de la candidemia en neonatos en América Latina
Santolaya, M. E., Matute, T. A., Telles, F. D. Q., Colombo, A. L., Zurita, J., Tiraboschi, I. N., Cortés, J. A., Thompson-Moya, L., Guzmán-Blanco, M., Sifuentes‐Osornio, J., et al. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.06.002 · Cited by 18
Innovation of Novel Antibiotics: An Economic Perspective
McKellar, M. R., & Fendrick, A. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu530 · Cited by 15
Wenzler, E., Wong, J. R., Goff, D. A., Jankowski, C. A., & Bauer, K. A. A. (2016) · Antibiotics · doi:10.3390/antibiotics5010006 · Cited by 15
“As time to appropriate antimicrobial therapy has been shown to be the single most important predictor of mortality in patients with infectious disease syndromes [38–41], identifying the causative pathogen and its resistance mechanisms sooner is extremely valuable for the optimization of patient care.”
BackgroundChen, Y., Kuo, S., Chen, F., & Lee, C. (2016) · Mycoses · doi:10.1111/myc.12553 · Cited by 15
Uppuluri, P., Khan, A. A., & Edwards, J. E. (2017) · Springer eBooks · doi:10.1007/978-3-319-50409-4_2 · Cited by 18
“Studies suggest that initiating treatment is more important than the choice of antifungal therapy (Morrell et al. 2005; Garey et al. 2006; Clancy and Nguyen 2012).”
BackgroundMontoya, A. M., Luna-Rodríguez, C. E., Gracia-Robles, G., Rojas, O. C., Treviño‐Rangel, R. D. J., & González, G. M. (2019) · Mycologia · doi:10.1080/00275514.2019.1585161 · Cited by 16
“…most cases have been related to fungemia (Colombo et al. 1999, 2003a; Krcmery et al. 1999; Ng et al. 1999; Pappas et al. 2003; Rodero et al. 2005; Garey et al. 2006; da Matta et al. 2007; Chen et al. 2009; Behera et al. 2010; Singh et al. 2011; Tay et al. 2011; Santhanam et al. 2013; Cornely et…”
BackgroundCandida pneumonia: What we know and what we don’t
Barkauskas, C. E., & Perfect, J. R. (2009) · Current Fungal Infection Reports · doi:10.1007/s12281-009-0004-z · Cited by 16
Treatment options in candidaemia
Karthaus, M., & Cornely, O. A. (2007) · Mycoses · doi:10.1111/j.1439-0507.2007.01379.x · Cited by 19
Zilberberg, M. D., Yu, H.-T., Chaudhari, P., Emons, M. F., Khandelwal, N., & Shorr, A. F. (2014) · Critical Care · doi:10.1186/s13054-014-0590-1 · Cited by 15
“Many studies in both candidemia and other serious infections have noted a significant and clinically important rise in the risk of death when the patient does not receive prompt empiric treatment with an agent that covers the culprit pathogen [20-22].”
BackgroundSystemic hematogenous dissemination of mouse oral candidiasis is induced by oral mucositis
Katagiri, H., Fukui, K., Nakamura, K., & Tanaka, A. (2018) · Odontology · doi:10.1007/s10266-018-0366-1 · Cited by 15
“The mortality rate is also reported to increase with delayed introduction of antifungal drug administration [29].”
Evaluation of Candida bloodstream infection and antifungal utilization in a tertiary care hospital
Marins, T. A., Marra, A. R., Edmond, M. B., Martino, M. D. V., Yokota, P. K. O., Mafra, A. C. C. N., & Durão, M. S. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3094-9 · Cited by 15
“Regarding the timing of initiation of empiric treatment, studies are still controversial, with some showing that mortality was lower in patients who received the antifungal early [10, 11] and others indicating that there was no significant difference in in-hospital mortality [12, 13].”
BackgroundInfluentialMagnusiomyces capitatus fungemia: The value of direct microscopy in early diagnosis
Alobaid, K., Abdullah, A. A., Ahmad, S., Joseph, L., & Khan, Z. (2019) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2019.07.009 · Cited by 15
Goudjil, S., Chazal, C., Moreau, F., Leke, A., Kongolo, G., & Chouaki, T. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1191064 · Cited by 15
“onset of the infection are the two most critical factors to ensure a favorable outcome [5,6].”
BackgroundZaragoza, R., Llinares, P., Maseda, E., Ferrer, R., & Rodríguez, A. H. (2013) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.05.006 · Cited by 14
Price, J. S., Fallon, M., Posso, R. B., Backx, M., & White, P. L. (2022) · Journal of Fungi · doi:10.3390/jof8090935 · Cited by 15
“Treatment for invasive candidiasis (IC) is time-critical, with delayed treatment associated with higher hospital mortality [1].”
BackgroundZhao, Y.-S., Lai, Q., Tang, H., Luo, R.-J., He, Z., Huang, W., Wang, L., Zhang, Z., Lin, S., Qin, W., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1386161 · Cited by 14
Xia, R., & Wang, D. (2019) · Medicine · doi:10.1097/md.0000000000017704 · Cited by 14
Li, J., Jin, Z., Li, J., Su, L.-Y., Wang, Y.-X., Zhang, Y., Qin, D., Rao, G.-X., & Wang, R. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114201 · Cited by 14
Nakada, N., Miyazaki, T., Ueda, T., Yamagishi, Y., Yamada, K., Kawamura, H., Kakeya, H., Mukae, H., Mikamo, H., Takesue, Y., et al. (2021) · Mycoses · doi:10.1111/myc.13380 · Cited by 14
„Tarragona-Strategie“ – adäquate Antibiotikatherapie auf der Intensivstation
Engelmann, L., & Schmitt, D. (2014) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-013-0310-7 · Cited by 18
Forstner, C., Lassnigg, A. M., Tobudic, S., Schiferer, A., Fischer, H., Graninger, W., Steinlechner, B., Frantal, S., & Presterl, E. (2013) · Journal of Infection · doi:10.1016/j.jinf.2013.02.003 · Cited by 14
Gökbolat, E., Öz, Y., & Metintaş, S. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000434 · Cited by 15
“However, increased use of empirical antifungal therapy to avoid treatment delays may cause their unnecessary use in patients without candidemia, in addition to increased toxicity and cost [2].”
BackgroundInfluentialVecchione, A., Florio, W., Celandroni, F., Barnini, S., Lupetti, A., & Ghelardi, E. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02400 · Cited by 14
“, 2014, 2017), especially when they are not timely and appropriately treated (Garey et al., 2006).”
BackgroundRecent advances and novel approaches in laboratory-based diagnostic mycology
White, P. L. (2018) · Medical Mycology · doi:10.1093/mmy/myy159 · Cited by 14
Radić, M., Goić-Barišić, I., Novak, A., Rubić, Ž., & Tonkić, M. (2016) · Medical Mycology · doi:10.1093/mmy/myw012 · Cited by 16
Candida : What Should Clinicians and Scientists Be Talking About?
Spellberg, B. J., Marr, K. A., & Filler, S. G. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch1 · Cited by 15
Chen, H., Suda, K. J., Turpin, R. S., Pai, M. P., Bearden, D. T., & Garey, K. W. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x182130 · Cited by 14
Self-citationGrau, S., Salavert, M., Laderas, J. C. P., Vargas, M., Barrueta, J. A., & Mir, N. (2013) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2013.05.004 · Cited by 15
Clancy, C. J., Shields, R. K., & Nguyen, M. H. (2016) · Journal of Fungi · doi:10.3390/jof2010010 · Cited by 13
“Prompt antifungal treatment improves outcomes [2,3], but gold standard diagnostic tests (blood or deep-tissue site cultures) are ~50% sensitive, have turn-around times of several days, and often turn positive late in the disease [4].”
BackgroundManagement of patients with septic shock due toCandidainfection
Bassetti, M., Vena, A., & Russo, A. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1518104 · Cited by 14
Evaluation of the updated “Candida score” with Sepsis 3.0 criteria in critically ill patients
Li, D., Zhang, J., Han, W., Bai, G., Cheng, W., & Cui, N. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-995 · Cited by 13
“Based on relatively recent studies, intensivists have progressively recognized the significance of early identification of patients at high risk of ICI and the association between delayed antifungal therapy and increased mortality in these patients [18-20].”
BackgroundPredictors of Candida spp. as causative agents of catheter-related bloodstream infections
Nagao, M., Hotta, G., Yamamoto, M., Matsumura, Y., Ito, Y., Takakura, S., & Ichiyama, S. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.08.003 · Cited by 16
Micek, S. T., Arnold, H. M., Juang, P., Hampton, N. B., McKenzie, M., Scolarici, M. J., & Kollef, M. H. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.06.028 · Cited by 14
Cui, N., Wang, H., Qiu, H., Li, R., & Liu, D. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.02.019 · Cited by 13
The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus
Ostrosky-Zeichner, L. L., & Andes, D. R. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix239 · Cited by 14
Walker, B. S., Schmidt, R. L., Tantravahi, S. K., Kim, K., & Hanson, K. E. (2019) · Transplant Infectious Disease · doi:10.1111/tid.13148 · Cited by 15
Park, S. Y., Lee, J. S., Oh, J., & Park, J. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05117-0 · Cited by 13
Species identification and antifungal susceptibility of uncommon blood yeast isolates
Li, M.-C., Tang, H.-J., Wu, C.-J., Wang, S.-W., Su, S.-L., Liu, W., Ko, W., & Chen, Y. (2021) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2021.01.009 · Cited by 14
Histopathological Study of Candidal Infection in the Central Nervous System
Nakayama, H., Shibuya, K., Kimura, M., Ueda, M., & Iwabuchi, S. (2010) · Nippon Ishinkin Gakkai Zasshi · doi:10.3314/jjmm.51.31 · Cited by 13
Rapid electrochemical identification of pathogenic Candida species
Muir, A. K. S., Jenkins, A. T. A., Forrest, G., CLARKSON, J. M., & Wheals, A. E. (2009) · Journal of Medical Microbiology · doi:10.1099/jmm.0.009183-0 · Cited by 13
“Rapid detection of fungal species is essential, as a delay in initiation of therapy by even 24 h can lead to a significant increase in mortality (Garey et al., 2006), whilst a varying spectrum of susceptibility to antifungal agents exhibited by clinically relevant fungi means that identification to the species level i…”
BackgroundUse of T2MR in Invasive Candidiasis with and Without Candidemia
Zacharioudakis, I. M., Zervou, F. N., & Mylonakis, E. E. (2018) · Future Microbiology · doi:10.2217/fmb-2018-0079 · Cited by 13
Clinical predictors of candidemia in medical non-neutropenic, non-ICU patients. The CaMed score
Ruiz‐Ruigómez, M., Dueñas, C., Hernandez, C., García, D. V., Coronado-Álvarez, N. M., Portillo-Tuñón, V., Cardozo, C., Muñoz‐Medina, L., Cabo-Magadán, R., Luna, J. D. D., et al. (2018) · International Journal of Clinical Practice · doi:10.1111/ijcp.13275 · Cited by 14
Zatta, M., Bella, S. D., Giacobbe, D. R., Puente, F. D., Merelli, M., Azzini, A. M., Brugnaro, P., Vedovelli, C., Cattelan, A. M., Busetti, M., et al. (2020) · Gerontology · doi:10.1159/000510638 · Cited by 15
Ghanem‐Zoubi, N., Zorbavel, D., Khoury, J., Geffen, Y., Qasum, M., Predescu, S., & Paul, M. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3389-1 · Cited by 13
Husni, R., Chrabieh, R., Dib, R. W., Vázquez, J. A., Guimarães, T., Fernandez, A. R., Khoury, R., Asmar, L., Khazen, G., Samaha, N. L., et al. (2021) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2021.031 · Cited by 13
Lee, W., Liew, Y., Chlebicki, M. P., Ong, S. G. K., Lee, P., & Kwa, A. L. (2014) · Critical Care Research and Practice · doi:10.1155/2014/479413 · Cited by 14
Candidemia in the critically ill: initial therapy and outcome in mechanically ventilated patients
Ferrada, M. A., Quartin, A. A., Kett, D. H., & Morris, M. I. (2013) · BMC Anesthesiology · doi:10.1186/1471-2253-13-37 · Cited by 12
“Rapid initiation of antifungal therapy improves survival, but previous studies have not addressed initial treatment [10-12,26].”
BackgroundLewis, R. E. (2011) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3181ff7e10 · Cited by 12
“Early treatment of IFIs is critical for successful clinical outcomes; studies have shown that delaying antifungal therapy independently increases the risk of death.(30,31) Early therapy improves outcomes in patients with candidiasis,(30,31) aspergillosis,(32,33) and mucormycosis.”
BackgroundXafranski, H., Melo, A. S. D. A., Machado, A. M. O., Briones, M. R. S., & Colombo, A. L. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-467 · Cited by 14
“Early diagnosis of this infection is essential for proper antifungal therapy, and delays of more than 12 hours in the administration of antifungal agents may substantially increase mortality [9].”
BackgroundAnidulafungin in the treatment of patients with invasive candidiasis
Kett, D. H., & Cubillos, G. F. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70008-6 · Cited by 12
“In a study of 230 patients with candidemia, Garey and colleagues [4] found that mortality rates were lowest for patients who initiated antifungal therapy on day 0 of a”
BackgroundGarnacho‐Montero, J., Díaz‐Martín, A., & Cayuela, A. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70015-3 · Cited by 12
Slechta, E. S., Hohmann, S. L., Simmon, K. E., & Hanson, K. E. (2012) · Medical Mycology · doi:10.3109/13693786.2011.630683 · Cited by 12
Ahmadi, A., Ardehali, S. H., Beigmohammadi, M. T., Hajiabdolbaghi, M., Hashemian, S. M. R., Kouchek, M., Majidpour, A., Mokhtari, M., Moghaddam, O. M., Najafi, A., et al. (2014) · JRSM Open · doi:10.1177/2042533313517689 · Cited by 14
“Figure 1 illustrates a simple scheme for these approaches.(31,46,47) According to the most recent IDSA guideline,(35) the empirical therapy against IC in non-neutropenic adult patients should include fluconazole for the less critically ill patient with no recent azole exposure, and echinicandins (caspofungin, micafung…”
MethodBailly, S., Garnaud, C., Cornet, M., Pavèse, P., Hamidfar-Roy, R., Foroni, L., Boisset, S., Timsit, J., & Maubon, D. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2633-9 · Cited by 12
Kumar, S., Kalam, K., Ali, S., Siddiqi, S., & Baqi, S. (2014) · PubMed · Cited by 21
Pharmacogenomics of Antifungal Agents
Ashbee, H. R., & Gilleece, M. H. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386882-4.00038-4 · Cited by 13
“Whatever approach is used, it is recognized that the successful outcome of an IFD relies on the early institution of appropriate antifungal therapy and that successful outcomes correlate with early initiation of therapy [63].”
BackgroundBordallo-Cardona, M. Á., Marcos-Zambrano, L. J., Sánchez‐Carrillo, C., Bouza, E., Muñóz, P., Escribano, P., & Guinea, J. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00162-18 · Cited by 14
Andrés, M. V., Català, C., Casadó‐Llombart, S., Martínez‐Florensa, M., Simões, I., García‐Luna, J., Mourglia‐Ettlin, G., Zaragoza, Ó., Carreras, E., & Lozano, F. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01103-20 · Cited by 12
“No significant reductions of the morbidity and mortality of IFDs have been achieved, despite the available antifungals, as a result of inherent or acquired drug resistance, drug interactions, and significant drug-associated toxicities (2).”
BackgroundMaraki, S., Katzilakis, N., Neonakis, I., Stafylaki, D., Meletiadis, J., Hamilos, G., & Stiakaki, E. (2022) · Mycopathologia · doi:10.1007/s11046-022-00658-1 · Cited by 12
“It is known that delays in diagnosis and administration of the appropriate treatment are associated with worse outcomes [34].”
BackgroundExisting and emerging therapies for the treatment of invasive candidiasis and candidemia
Bels, D. D., Maillart, E., Bambeke, F. V., Redant, S., & Honoré, P. M. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2142207 · Cited by 12
Anidulafungin: an evidence-based review of its use in invasive fungal infections.
Davis, S. L., & Vázquez, J. A. (2008) · PubMed Central · Cited by 13
Ostrosky-Zeichner, L. L., Paetznick, V. L., Rodriguez, J., Chen, E., & Sheehan, D. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00955-08 · Cited by 12
“Recent research has shown that even minor delays in appropriate antifungal therapy are associated with increased morbidity and mortality and that it is difficult to predict non-albicans Candida species infection reliably (2, 3).”
Backgroundvan der Geest, P. J., Hunfeld, N., Ladage, S. E., & Groeneveld, A. B. J. (2016) · BMC Infectious Diseases · doi:10.1186/s12879-016-1825-3 · Cited by 12
“The mortality of invasive candidiasis is directly correlated with a delay in starting antifungal therapy and therefore early treatment with an appropriate antifungal drug is mandatory [6, 7].”
BackgroundCambios clínicos y epidemiológicos de candidemias en pacientes adultos desde 2000 a 2013
Sin, L., Legarraga, P., García, P., González, T. C., & Ricardo Rabagliati, B. (2017) · Revista chilena de infectología · doi:10.4067/s0716-10182017000100003 · Cited by 18
Vlieger, G. D., Ingels, C., Wouters, P. J., Debaveye, Y. A., Vanhorebeek, I., Wauters, J., Wilmer, A. P., Casaer, M. P., & den Berghe, G. V. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.05.017 · Cited by 13
Systemic Candidiasis: Candidemia and Deep-Organ Infections
Clancy, C. J., & Nguyen, M. H. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch27 · Cited by 15
Neurological Manifestations of Infectious Diseases: Insights From Recent Cases
Kashyap, J., Olanrewaju, O. A., Mahar, K., Israni, M., Bai, R., Kumar, N., Kumari, K., Shadmani, S., Bashir, M. A., Elharif, M., et al. (2023) · Cureus · doi:10.7759/cureus.51256 · Cited by 13
“The outlook for patients with neurological symptoms in infectious diseases varies greatly depending on factors such as the particular pathogen, the extent of neurological involvement, the promptness of treatment, and other existing health conditions [40].”
BackgroundInfluentialRetractedManagement of Intra-Abdominal Candidiasis in Intensive Care Setting: A Narrative Review
Pais, M. M., Zaragoza, R., Martín‐Loeches, I., Gómez-Bertomeu, F., & Rodríguez, A. H. (2025) · Journal of Fungi · doi:10.3390/jof11050362 · Cited by 12
“This finding has been replicated by other researchers [45,46].”
InfluentialMicrobial Spectrum and Antibiotic Resistance in Patients Suffering from Penetrating Crohn’s Disease
Kusan, S., Surat, G., Kelm, M., Anger, F., Kim, M., Germer, C., Schlegel, N., & Flemming, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11154343 · Cited by 12
Molecular Techniques and Target Selection for the Identification of Candida spp. in Oral Samples
Magalhães, J., Correia, M. J., Silva, R. M., Esteves, A. C., Alves, A., & Duarte, A. S. (2022) · Applied Sciences · doi:10.3390/app12189204 · Cited by 16
“…mortality rates in Candida infections are in part justified by diagnostic inaccuracy (i.e., incorrect identification at the species level and of the drug resistance profile), which may compromise the administration of adequate antifungal therapies and ultimately lead to the patient’s death [27–29].”
BackgroundDiagnostic Mycology Laboratories Should Have a Central Role for the Management of Fungal Disease
Medina, N., Alastruey‐Izquierdo, A., Mercado, D., Denning, D. W., Arathoon, E., & Rodríguez-Tudela, J. L. (2022) · Journal of Fungi · doi:10.3390/jof8121285 · Cited by 11
“For fungal diseases, early diagnosis and the institution of active antifungal therapy are directly linked to improved survival [10,11].”
BackgroundUpdate: invasive Pilzinfektionen
Lichtenstern, C., Swoboda, S., Hirschburger, M., Domann, E., Hoppe‐Tichy, T., Winkler, M., Lass‐Flörl, C., & Weigand, M. A. (2010) · Der Anaesthesist · doi:10.1007/s00101-009-1655-4 · Cited by 12
Neoh, C. F., Liew, D., Slavin, M. A., Marriott, D., Chen, S. C. ‐., Morrissey, O., Stewart, K., & Kong, D. C. M. (2013) · Mycoses · doi:10.1111/myc.12071 · Cited by 12
Farina, C., Manso, E., Andreoni, S., Conte, M., Fazii, P., Lombardi, G., Sanna, S., & Russello, G. (2011) · PubMed · Cited by 11
Risk factors for early invasive fungal infections in paediatric liver transplant recipients
Pasternak, Y., Rubin, S., Bilavsky, E., Mozer‐Glassberg, Y., Levy, I., Nahum, E., Rom, E., Gurevich, M., Ben‐Zvi, H., & Ashkenazi‐Hoffnung, L. (2018) · Mycoses · doi:10.1111/myc.12784 · Cited by 11
Diagnóstico microbiológico de las micosis invasoras
García, J. M., & Pemán, J. (2018) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2018.05.003 · Cited by 13
Metadata
- Authors
- Garey, K. W., Rege, M., Pai, M. P., Mingo, D. E., Suda, K. J., Turpin, R. S., & Bearden, D. T.
- Affiliations
- University of Houston (US)
- University of New Mexico (US)
- Baptist Memorial Health Care (US)
- University of Tennessee Health Science Center (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Oregon State University (US)
- Corresponding author
- Garey, Kevin W.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-07
- Volume
- 43
- Issue
- 1
- Pages
- 25-31
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2164001967
- Semantic Scholar
- e1a67fd5e540307550577ea7a071370b075e943f
- Cited by
- 1,171
- References
- 20
- Citations by year
- 2026: 31 · 2025: 26 · 2024: 31 · 2023: 31 · 2022: 49 · 2021: 67 · 2020: 51 · 2019: 51 · 2018: 62 · 2017: 66 · 2016: 61 · 2015: 74 · 2014: 87 · 2013: 83 · 2012: 77
- FWCI
- 35.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Enzon Pharmaceuticals
- University of Houston
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Keywords
- candidemia, fluconazole, treatment delay, mortality, fungemia, Candida albicans, APACHE II score, mortality risk factors, hospitalized patients, Candida tropicalis, Candida parapsilosis, Candida glabrata, diabetes mellitus, cancer patients, sepsis
- MeSH terms
- Adult, Aged, Antifungal Agents, Candidiasis, Female, Humans, Length of Stay, Male, Middle Aged, Retrospective Studies, Time Factors, Cohort Studies, Fluconazole, Fungemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.